Neurocrine Biosciences Inc. Sets New 1-Year High at $18.44 (NBIX)
Neurocrine Biosciences (NASDAQ:NBIX) set a new 52-week high during mid-day trading on Tuesday, Analyst RN reports. The stock traded as high as $18.44 and last traded at $18.09, with a volume of 16,887,153 shares. The stock had previously closed at $9.76.
NBIX has been the subject of a number of recent research reports. Analysts at Deutsche Bank raised their price target on shares of Neurocrine Biosciences from $18.00 to $25.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Separately, analysts at MKM Partners raised their price target on shares of Neurocrine Biosciences from $13.00 to $17.00 in a research note to investors on Tuesday. They now have a “buy” rating on the stock. Finally, analysts at Roth Capital raised their price target on shares of Neurocrine Biosciences from $16.00 to $22.00 in a research note to investors on Tuesday. One analyst has rated the stock with a hold rating and ten have given a buy rating to the company. Neurocrine Biosciences has a consensus rating of “Buy” and a consensus target price of $18.56.
Neurocrine Biosciences has a 1-year low of $8.08 and a 1-year high of $16.74. The stock’s 50-day moving average is $9.41 and its 200-day moving average is $11.75. The company’s market cap is $1.210 billion.
Neurocrine Biosciences (NASDAQ:NBIX) last issued its quarterly earnings data on Tuesday, October 29th. The company reported ($0.17) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.03. The company had revenue of $0.73 million for the quarter, compared to the consensus estimate of $0.79 million. During the same quarter in the previous year, the company posted ($0.05) earnings per share. The company’s revenue for the quarter was down 92.2% on a year-over-year basis. On average, analysts predict that Neurocrine Biosciences will post $-0.72 earnings per share for the current fiscal year.
Neurocrine Biosciences, Inc (NASDAQ:NBIX) discovers, develops and commercializes drugs for the treatment of neurological and endocrine-related diseases and disorders.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.